NCT03021460 2026-01-20Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryMayo ClinicPhase 1 Active not recruiting20 enrolled
NCT02581930 2025-09-08Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous MelanomaNational Cancer Institute (NCI)Phase 2 Active not recruiting18 enrolled 10 charts